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Abstract
Background and aims We evaluated the outcome of
primarily resected rectal cancer patients immediately after
the implementation of total meserectal excision (TME)
based on potential quality indicators.
Patients and methods Following initial teaching of two staff
surgeons (PMS and AHH) by RJ Heald, 164 consecutive
patients were analyzed. The following quality indicators were
evaluated: (a) frequency of local recurrence, (b) number of
resected lymph nodes, (c) selection of operative technique
depending on tumor localization, (d) use of a protective loop
ileostomy, and (e) frequency and type of adjuvant therapy.
Results Local recurrence rate was 8.5% after a minimum
follow-up of 5 years. An increasing pT category (p<0.02)
and the presence of lymph node metastases (pN+, p<0.05)
were significantly associated with local recurrence rates.
The number of resected lymph nodes was significantly
associated with nodal metastases rate (p<0.02). Patients
with distal third rectal cancer underwent significantly more
often an abdominoperineal amputation (p<0.0001). Clinical
course, but not the rate of anastomotic leakage (9.5%) itself
was influenced by using a protective loop ileostomy. Forty-
two (29.7%) patients received adjuvant therapy; however,
local recurrence rate was higher in patients with adjuvant
chemo-/radiotherapy (14.2% vs. 6.1%).
Conclusions The local recurrence rate of 8.5% demonstrates
that through consequent implementation of TME excellent
onclogical results can be achieved. The number of resected
lymph nodes significantly influenced the pN category. The
primary construction of a protective loop ileostomy after TME
became standard. Neoadjuvant chemoradiation was system-
atically introduced in order to improve local tumor control and
prevent abdominoperineal amputations. No conclusions can
be drawn concerning adjuvant therapy.
Keywords Rectal cancer . Surgical therapy . Total
mesorectal excision
Introduction
Quality assurance in oncologic surgery is increasingly
accepted as an important factor that affects the clinical
outcome of patients [1, 2]. This applies particularly for
rectal cancer that requires a demanding, meticulous surgical
technique. Heald et al. [3] proposed the method of total
mesorectal excision (TME) which necessitates complete
excision of the mesorectal tissue to the level of the levators
with simultaneous preservation of autonomic nerve func-
tion. This technique has certainly improved the outcome of
patients with rectal cancer by significantly reducing the
local recurrence rate and became the standard surgical
procedure in rectal cancer treatment [4, 5].
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In addition, multiple studies assesed the relationsship
between surgeon/hospital volume and clinical outcome of
patients with rectal cancer. For example, Harmon et al.
examined the association of surgeon and hospital case
volumes with the outcome of patients with colorectal
cancer. They showed that “medium-volume” surgeons
achieved excellent outcomes similar to “high-volume”
surgeons when operating in “medium-volume” or “high-
volume” hospitals, while the results of “low-volume”
surgeons improved with increasing hospital volume but
never reached those of the “high-volume” surgeons [6]. In
contrast, Marusch et al. [7] failed to show significant
associations between hospital caseload and postoperative
outcome in 2,293 colorectal cancer patients undergoing
surgery.
Even though controversial data are available about the
volume–quality relationship, a limitation on the perfor-
mance of rectal cancer surgery to highly specialized
surgeons is impractical in view of the prevalence of rectal
cancer. As evidence suggests that training is a prerequisite
to obtain good results in surgeons’ hands; in the last years,
many countries have focused on improvements in the
training of rectal surgery [8–10]. For instance, Wibe et al.
[10] performed a prospective study to assess the influence
of educational programs and training courses in Norway.
They verified that the prognosis of rectal cancer patients
was significantly improved by the increased organizational
focus on rectal cancer treatment with a significant reduction
of local recurrence [10].
To evaluate and improve this training in rectal surgery
and also to improve the overall quality assurance in
rectal cancer treatment, a data set with defined quality
indicators has to be established. The purpose of this
study was evaluate the outcome of primary resected
rectal cancer patients after the implementation of partial
mesorectal excision (PME) and TME by the following
potential quality indicators: (1) number of lymph nodes
analyzed in the surgical specimen, (2) selection of
operative technique depending on tumor localization,
(3) primary construction of a protective loop ileostomy
to prevent complications due to an anastomotic leakage,
(4) frequency of local recurrence rate, and (5) frequency
of adjuvant therapy.
Patients and methods
On February 20, 1997, Professor Heald from Basingstoke,
England, introduced the TME technique in the Department
of General, Visceral and Cancer Surgery, University of
Cologne, Cologne, Germany by teaching PMS and AHH.
In addition, a prospective database was set up immediately
for all rectal cancer patients treated newly in our institution.
The presented analysis includes 164 primarily resected
patients (intention to treat) between February 1997 and
December 2004 out of 234 patients. Forty-eight patients
receiving neoadjuvant chemoradiation and 22 patients
undergoing local resection by transanal endoscopic micro-
surgery were excluded. The last follow-up was December
2009 ensuring a minimum follow-up of 5 years after
resection for surviving patients.
This study was performed in accordance with the
guidelines of the local Institutional Review Board.
Diagnostic and staging procedures
TNM staging was performed according to the criteria of the
International Union Against Cancer [11]. Clinical staging
consisted of endoscopy, endoscopic ultrasound, CT
scanning of the abdomen, and thorax. Classification of
localization was performed using rigid rectoscopy using the
distance of the anocutaneous line to the lower border of the
tumor according to TNM supplement, 3rd edition, as
follows:
Upper rectal third 12–16 cm
Middle rectal third 6≤12cm
Lower rectal third <6 cm
Surgical resection and adjuvant therapy
The patients underwent three surgical procedures
depending on the tumor localization: (1) anterior resec-
tion with partial PME, (2) low anterior rectal resection
with TME, and (3) abdominoperineal rectum amputation
with TME.
Adjuvant therapy was not delivered by protocol and was
mainly offered to patients with Union for International
Cancer Control (UICC) stage III, generally using chemo-
therapy, next to radio- and radiochemotherapy.
Follow up
Patients were under regular follow-up, undergoing colono-
scopy, CT scan of chest and abdomen, and ultrasound of the
liver up to 5 years.
Statistical analysis
Data were collected prospectively according to a
standardized protocol. Chi-square statistics were calcu-
lated for frequencies of factors. Kaplan–Meier plots
were used to describe survival distribution and the log-
rank test was used to evaluate for survival differences.
Postoperative mortality was included in the calculation
904 Int J Colorectal Dis (2011) 26:903–909
of prognosis. The level of significance was set to p<
0.05 in all tests.
All statistical analyses were performed using the statistic
program SPSS for Windows version 17.0.
Results
Demographic and clinical parameters of study patients
There were 61 women (37.2) and 103 men (62.8%) with a
median age of 64.4 years (range, 34–87 years). Of these, 160
patients underwent primary surgical resection, while four
patients received palliative chemotherapy because of diffuse
metastatic disease confirmed by explorative laparotomy
without resection. In 156 (97.5%) patients, an R0 resection;
in two, (1.25%) an R1 resection; and in two (1.25%) patients,
an R2 resection of the primary tumor was performed.
Distant metastases were detected in 49 (29.8%) patients.
From these, 30 (18.3%) patients had synchronous and 19
(11.5%) metachronous distant metastases. Thirteen (7.9%)
patients with synchronous metastases underwent surgical
resection of the metastases.
Analysis of potential quality indicators
Number of analyzed lymph nodes in the surgical specimen
According to the UICC guidelines, patients were classified
into two groups: (a) patients with 12 or more resected
lymph nodes (n=91; 56.9%) and (b) patients with less than
12 lymph nodes analyzed in the surgical specimen lymph
nodes (n=69; 43.1%) [11]. Higher lymph node retrieval
was significantly associated with a higher histopathologic
nodal metastases rate (p<0.02; Table 1).
No significant difference (p=0.71, log-rank test) in
terms of survival was observed between the two groups.
Patients with ≥12 lymph nodes analyzed in the surgical
specimen had a median survival of 79.21 months (95%
CI, 73.34–85.07 months) and patients with <12 had a
median survival of 81.11 months (95% CI, 74.55–
87.66 months).
Selection of the operative technique depending on tumor
localization
Distribution of tumor localization was as follows: 58
patients had an upper third, 64 a middle third, and 42 a
lower third rectal cancer. The patients underwent
predominantly three surgical procedures: (a) anterior
resection (n=48, 29.2%), (b) low anterior resection
(n=68, 41.5%), and (c) abdominoperineal amputation
(n=40, 24.4%; Table 2).
A significant association was detected between tumor
localization and surgical procedure. Patients with lower
third rectal cancer underwent significantly more often
an abdominoperineal amputation compared to patients
with upper or middle third rectal cancer (p<0.0001,
Table 3).
Tumor localization was also significantly associated with
the pT category: patients with a lower third rectal cancer
undergoing an abdominoperineal amputation had signifi-
cantly more often a pT3/4 category than patients undergo-
ing low anterior resection.
Construction of a protective loop ileostomy
In 28 (24.1%) patients, a protective ileostomy was
constructed. The overall anastomotic leakage rate was
9.5% (11 patients). There was no difference in overall leak
rates between patients with and without a protective loop
Table 1 Correlation between the number of analyzed lymph nodes in
the surgical specimenand pN category
Resected lymph nodes pN0 stage (%) pN1–2 stage Total
<12 51 (32.1) 18 (11.9) 69
≥12 46 (28.9) 43 (27.7) 91
p<0.02; χ² test
Table 2 Surgical procedure and tumor localization; distribution of
operative techniques
Operative technique Patients (n) %
Standard procedures
Anterior resection 48 29.2
Low anterior resection 68 41.5
Abdominoperineal amputation 40 24.4
Other procedures
Hartmann’s procedure 2 1.2
Proctocolectomy 2 1.2
Diagnostic laparotomy 4 2.4
Table 3 Surgical procedure and tumor localization; operative tech-
nique depending on tumor localization
Localization Anterior
resection
(%)
Low
anterior
resection
(%)
Abdominoperineal
amputation (%)
Total
Upper third 41 (75.9) 13 (24.1) 0 (0) 54
Middle
third
7 (11.3) 49 (79) 6 (9.7) 62
Lower third 0 (0) 6 (15) 34 (85) 40
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ileostomy (Table 4). However, a protective ileostomy
significantly reduced the incidence of anastomotic leakage
that became symptomatic and required surgical interven-
tion. Six out of seven patients without a protective
ileostomy became symptomatic due to a leakage and
required surgical revision, where as none of the patients
with a protective stoma needed a relaparotomy due to
anastomotic leackage.
In addition, a significant correlation was observed
between the leakage rate in patients without a protective
stoma and surgical procedure: patients undergoing anterior
resection had significant fewer leaks compared to patients
undergoing a low anterior resection (three vs. eight patients;
p<0.05, Table 5).
Frequency of local recurrence
With a minimum follow-up of the surviving patients of
60 months, 12 from 136 (8.8%) patients (five patients
were lost to follow-up) patients developed local recur-
rence after R0 resection. Analysis of risk factors for
local recurrence revealed that an advanced pT category
and the pN category was a risk factor for local
recurrence (see Table 5, 6, and 7). Tumor localization
merely showed a tendency towards frequency of local
recurrences.
Frequency of adjuvant therapy
Adjuvant therapy was not standardized and left to the
discretion of the consultant surgeon. Forty-two (29.7%)
patients with R0 resection received an adjuvant therapy,
most of them (n=26, 61.9%) with an histopathologic UICC
stage III (Table 8). Six of the 42 (14.2%) patients developed
a local recurrence. From the patients receiving no adjuvant
therapy, six patients (6.1%) only developed local recurrence
(Table 9).
Discussion
The purpose of this study was to evaluate a data set of
quality indicators in primarily resected rectal cancer
patients after the implementation of TME. The following
potential quality indicators were analyzed: (1) number of
resected lymph nodes, (2) selection of operative technique
depending on tumor localization, (3) primary construction
of a protective loop ileostomy to prevent complications due
to an anastomotic leakage, (4) frequency of local recur-
rence, and (5) frequency of adjuvant therapy.
For a precise determination of the lymph node category,
the UICC recommend that a minimum of 12 lymph nodes
should be resected and recovered in colorectal cancer
patients undergoing surgical therapy [11]. This goal was
achieved in 56.9% of our study patients only and does not
meet the standard as suggested by Bittner et al. [12].
Moreover, we observed that tumors with a lymph node
Anastomotic leackage
No (%) Yes (%) Total (%)
Frequency of anastomotic leckage with and without a protective loop ileostomy
Protective stoma
No 81 (92) 7 (8) 88 (100)
Yes 24 (85.7) 4 (14.3) 28 (100)
Correlation between anastomotic leakage and type of surgical procedure
Surgical procedure
Anterior resection 45 (93.8) 3 (6.3) 48 (100)
Low anterior resection 60 (88.2) 8 (11.8) 68 (100)
Table 4 Frequency of anasto-
motic leckage with and without
a protective loop ileostomy and
correlation between anastomotic
leakage and type of surgical
procedure
Table 5 Local recurrence rate based on pT/pN categories and tumor
localization; pT category
pT
category
n Lost of follow
up (%)
Remaining Local
recurrence (%)
1 22 1 (5) 21 –
2 38 – 38 2 (5)
3 79 4 (5) 75 9 (12)
4 2 – 2 1 (50)
Total 141 5 (3.5) 136 12 (8.8)
p<0.02, χ² test
Table 6 Local recurrence rate based on pT/pN categories and tumor
localization; pN category
pN
category
n Lost of follow
up (%)
Remaining Local
recurrence (%)
0 93 2 (2.1) 91 5 (5.5)
1/2 47 2 (4.2) 45 7 (15.5)
Total 140 4 (2.8) 136 12 (8.8)
p<0.05, χ² test
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retrieval number ≥12 were significantly associated with a
higher nodal metastases rate (pN category). We could
however not demonstrate that the number of resected lymph
nodes had a prognostic impact. These findings are
consistent with recent studies evaluating the prognostic
influence of lymph node harvest in colorectal cancer
patients [13–15]. Kim et al. [14] demonstrated in a
retrospective study of 151 patients with colorectal cancer
that a higher number of lymph nodes resected/examined
were associated with a higher nodal metastasis rate. On the
other hand, Prandi et al. reported on 3,648 patients with
stage B colon cancer that patients with <7 nodes in the
specimen had both a shorter overall survival and relapse
free survival [13]. More recently, Tsai et al. [15] showed in
366 patients with T2-4N0M0 colorectal cancer undergoing
radical tumor resection that patients with 18 or more
examined lymph nodes had a significantly lower postoper-
ative relapse and a higher 5-year overall survival than
patients who had less than 18 nodes examined. Despite the
fact that the minimum number of lymph nodes examined
per surgical specimen is still under discussion, lymph node
retrieval should be used as a quality indicator in rectal
surgery, for both, surgeons and pathologists because the
number of resected/retrieved lymph nodes is important for
the detection of nodal metastases. In addition, nodal
metastases are significantly associated with local recurrence
rates and this again could influence whether postoperative
adjuvant therapy should be recommended.
Our study showed that patients with lower third rectal
cancer underwent significantly more often an abdomino-
perineal rectum amputation compared to patients having a
tumor in the upper or middle third. However, mainly locally
advanced tumors were resected by an amputation and
through the consequent implementation of neoadjuvant
chemoradiation, more sphincter-preserving operations
should be expected in our institution. This is in line with
observations from other studies that showed that through
improvement of surgical techniques and especially by
administering neoadjuvant chemoradiation, permanent
colostomy rates in patients with lower third rectal cancer
can be substantially reduced [16, 17]. Since evidence
suggests that the quality of life after anterior or low anterior
resection is usually improved compared with abdominoper-
ineal amputation, the selection of the operative techniques
depending on tumor localization might be used as good
quality indicator in rectal surgery [12, 18, 19].
We could also show that clinical symptoms but not the
very frequency of anastomotic leakage was influenced by
the primary construction of a protective loop ileostomy: six
of seven patients without a protective ileostomy became
symptomatic due to a leakage and surgical revision was
needed, whereas none of the patients with a primary
ileostomy needed a relaparotomy. Similar findings were
reported by Gastinger et al. [20] in a prospective multicen-
ter study that evaluated early outcome after low anterior
resection in patients with and without a protective stoma.
They showed that the overall anastomotic leakage rates
were similar in patients with or without a protective stoma
but the incidence of symptomatic leaks that required
surgical intervention was significantly lower in those with
a protective stoma. In addition, Matthiessen et al. [21]
assessed in a randomized multicenter trial the rate of
symptomatic anastomotic leakage in patients operated by
low anterior resection and were able to demonstrate that a
defunctioning loop stoma significantly decreased the
leakage rate. These data suggest that a protective stoma
should be recommended in low anterior resection for rectal
cancer to avoid serious complications of anastomotic
leackage.
In our study the local recurrence rate after a minimum
follow-up of 5 years was 8.5%. These data are in agreement
with the majority of studies reported in the literature after
Table 7 Tumor localization and local recurrence rates
Tumor
localization
n Lost of follow
up (%)
Remaining Local
recurrence
(%)
Upper third 50 5 (10) 45 6 (13.3)
Middle third 56 – 56 3 (5.3)
Lower third 35 – 35 3 (8.5)
Total 141 5 (3.5) 136 12 (8.8)
p=0.06, χ² test
Adjuvant therapy
UICC
stage
No adjuvant therapy
(%)
Chemotherapy
(%)
Radiochemotherapy
(%)
Radiotherapy
(%)
I 52 (100) 0 (0) 0 (0) 0 (0)
II 31 (83.8) 4 (10.5) 3 (7.9) 0 (0)
III 14 (35) 15 (37.5) 10 (25) 1 (2.5)
IV 2 (18.2) 8 (72.7) 1 (9.1) 0 (0)
Total 99 (70.2) 27 (19.1) 14 (9.9) 1 (0.7)
Table 8 Adjuvant therapy in
study patients; adjuvant therapy
depending on UICC stage
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the implementation of TME with recurrence rates between
5% and 10% [9, 22–25]. In fact, the radical surgical
approach with TME is the major determinant for the
significant decrease of local recurrence rates in the last
years and was shown to be an effective surrogate indicator
of treatment outcome quality [26]. Also, the minimum
requirement of 5 years follow-up for patients with surgery
alone as suggested by Merkel et al. [27] was fulfilled in our
study. We did however, not routinely evaluate the quality of
PME or TME by histopathological criteria as suggested by
Quirke and Morris [28] and therefore cannot rule out
technical surgical problems in our patients with observed
local recurrences. Tumor stage and lymph node involve-
ment and the use of (neo-) adjuvant therapy were also
described in the literature as prognostic factors influencing
local recurrence in rectal cancer. In our study, both the T
and N categories significantly predicted for a higher
recurrence rate [22–25]. In conclusion, the local recurrence
rate should be used as an important quality indicator in
rectal cancer surgery because it is a very sensitive
parameter determining the surgeons’ accuracy, i.e., the
correct performance of the TME technique [10, 12, 27, 28].
Our study results did not show that adjuvant therapy is
an effective treatment in rectal cancer patients following
TME. Actually, the local recurrence rate was higher in
patients receiving adjuvant therapy compared with patients
obtaining no postoperative treatment. Indeed, randomized
studies from the late 1980s and early 1990s established
postoperative radiochemotherapy as the standard of care for
patients with resected stage II/III rectal cancer [29–33]
when conventional blunt dissection with higher recurrence
rates were performed.
Since adjuvant therapy was not administered by a
standardized protocol, no conclusions can be drawn from
those results besides that it is important not only to
standardize operative techniques but also implement guide-
lines for adjuvant and neoadjuvant treatment modalities.
In 2004, the German Rectal Cancer Study demonstrated
that preoperative radiochemotherapy doubled the rate of
sphincter-sparing operations and significantly lowered the
rates of local recurrence compared to postoperative treat-
ment. Based on these convincing data, we implemented
neoadjuvant chemoradiation as standard treatment for
locally advanced middle and lower third rectal cancer in
2004 in our institution [34].
In summary, the following conclusions can be made: (1)
the number of analyzed lymph nodes in the surgical
specimen influences the pN category which is important
regarding the indication for adjuvant therapy. (2) The
primary construction of a protective loop ileostomy
significantly decreased the need for a surgical revision if
an anastomotic leakage occurred following low anterior
rescetion. (3) In contrast to neoadjuvant chemoradiation,
the value of adjuvant therapy after the implementation of
TME remains highly controversial, because it is at least
questionable if postoperative therapy additionally reduces
the local recurrence rates. (4) The local recurrence rate of
8.5% after a minimum follow-up of 5 years demonstrates
that through the consequent implementation of TME local
recurrence rates similar to the reported series from
internationally renowned groups can be achieved.
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